Enterome OncoMimics™ immunotherapy EO2401 shows survival benefit in Phase 2 glioblastoma trialParis, France – 2 DECEMBER 2025 (08:30 CET)Enterome, a clinical-stage company pioneering OncoMimics™ peptides, a new class of off-the-shelf, multi-targeted in vivo immune therapies that induce a fast and potent expansion of memory T cells to fight cancer, today announces new survival analyses from Cohort 3 of the Phase 1/2 ROSALIE clinical trial. The data were reported at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting. The ROSALIE trial is evaluating Enterome’s OncoMimics™ immune therapy EO2401 in combination with immune checkpoint inhibitor nivolumab, with or without anti-VEGF therapy bevacizumab, in patients with glioblastoma at first progression/recurrence. Top-line data from the trial had previously been released in November 2023.
Enterome to present positive interim Phase 2 data for lead OncoMimics™ immunotherapy EO2463 in follicular lymphoma at American Society for Hematology (ASH) meetingParis, France – 13 NOVEMBER 2025 (08:30 CET)Enterome, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted in vivo immune therapies that induce a fast and potent expansion of memory T-cells to fight cancer, today announced positive new interim data from two cohorts of patients with low tumor-burden follicular lymphoma in the ongoing Phase 2 study of its lead OncoMimics™ immunotherapy EO2463. In cohort 3, data from the SIDNEY study showed a benign safety profile for EO2463 in combination with rituximab as first-line treatment for previously untreated patients with low tumor-burden follicular lymphoma in need of treatment, adding only injection site reactions to the well-known safety profile of rituximab. In addition, all six patients in this feasibility assessment responded to the combination treatment.
Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463Paris, France – 16 OCTOBER, 2025 Enterome, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, announces today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for follicular lymphoma in the low tumor burden “watch-and-wait” setting for its lead OncoMimics™ immunotherapy, EO2463. The decision highlights EO2463’s efficacy, excellent safety and tolerability as a first-in-class monotherapy in clinical testing to date in patients who currently do not normally receive any treatment as long as they do not show clinical symptoms, despite having been diagnosed with a cancer that progresses in the vast majority of cases.
Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular LymphomaParis, France – June 12, 2025Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, has raised $19 million in a new private financing to advance its lead clinical program EO2463 OncoMimics™ immunotherapy to treat indolent non-Hodgkin lymphoma (iNHL). The new funds will be used to expand and finalize the ongoing Phase 1/2 SIDNEY clinical trial of EO2463 and prepare the candidate for a registrational trial.
Enterome to Host Webinar on New Clinical Data From the Ongoing Phase 1/2 ‘SIDNEY’ Trial of Lead Programme, EO2463
Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform, will be holding a webinar to run through new clinical data from the ongoing Phase 1/2 ‘SIDNEY’ trial of EO2463, for the treatment of patients with either newly diagnosed, previously untreated follicular lymphoma (FL) [EO2463 monotherapy], or FL and marginal zone lymphoma relapsed/refractory disease [EO2463 in combination with lenalidomide/rituximab].
